Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,886 questions in 74 reviews · Skin
current versionsNo studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any systemic treatment vs placebo Certolizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 12.11 [8.78, 16.71] | 4 studies · 1026 participants | Moderate |
Any systemic treatment vs placebo Ciclosporin · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 9.88 [5.45, 17.91] | 0 studies · 0 participants | Very low |
Any systemic treatment vs placebo Etanercept · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 9.72 [8.12, 11.63] | 14 studies · 5650 participants | Moderate |
Any systemic treatment vs placebo Methotrexate · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 9.78 [7.15, 13.37] | 3 studies · 318 participants | Low |
Any systemic treatment vs placebo Tofacitinib · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 8.19 [6.53, 10.29] | 5 studies · 3092 participants | Low |
Any systemic treatment vs placebo Apremilast · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 7.3 [4.26, 12.51] | 5 studies · 2029 participants | Moderate |
Any systemic treatment vs placebo Fumaric acid · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 3.65 [2.49, 5.36] | 1 study · 704 participants | Very low |
Any systemic treatment vs placebo Acitretin · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 2.13 [0.37, 12.16] | 0 studies · 0 participants | Very low |
Any systemic treatment vs placebo Ixekizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 28.12 [23.17, 34.12] | 4 studies · 3268 participants | Moderate |
Any systemic treatment vs placebo Methotrexate · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.43 [0.2, 0.95] | 3 studies · 319 participants | Moderate |
Any systemic treatment vs placebo Bimekizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.2 [0.01, 3.16] | 1 study · 250 participants | Low |
Any systemic treatment vs placebo Risankizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.6 [0.37, 0.96] | 4 studies · 1476 participants | Moderate |
Any systemic treatment vs placebo Certolizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.74 [0.31, 1.75] | 4 studies · 1026 participants | Low |
Any systemic treatment vs placebo Oral Tyrosine kinase 2 (TYK2) inhibitor · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.61 [0.06, 5.71] | 1 study · 267 participants | Low |
Any systemic treatment vs placebo Tildrakizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.84 [0.39, 1.83] | 3 studies · 1904 participants | Moderate |
Any systemic treatment vs placebo Apremilast · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.86 [0.48, 1.51] | 6 studies · 2290 participants | Low |
Any systemic treatment vs placebo Ustekinumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.89 [0.63, 1.27] | 10 studies · 4553 participants | Moderate |
Any systemic treatment vs placebo Etanercept · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.89 [0.61, 1.31] | 13 studies · 4265 participants | Moderate |
Any systemic treatment vs placebo Fumaric acid esters · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.98 [0.5, 1.94] | 1 study · 704 participants | Very low |
Any systemic treatment vs placebo Risankizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 27.67 [22.86, 33.49] | 4 studies · 1476 participants | High |
Any systemic treatment vs placebo Guselkumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.98 [0.54, 1.79] | 5 studies · 1767 participants | Moderate |
Any systemic treatment vs placebo Adalimumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 0.98 [0.65, 1.49] | 10 studies · 3485 participants | Moderate |
Any systemic treatment vs placebo Tofacitinib · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.01 [0.57, 1.77] | 7 studies · 3122 participants | Moderate |
Any systemic treatment vs placebo Brodalumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.04 [0.62, 1.73] | 5 studies · 4109 participants | Moderate |
Any systemic treatment vs placebo Infliximab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.11 [0.59, 2.07] | 6 studies · 1678 participants | Moderate |
Any systemic treatment vs placebo Ixekizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.09 [0.69, 1.73] | 4 studies · 3268 participants | Moderate |
Any systemic treatment vs placebo Ciclosporin · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.47 [0.19, 11.22] | 0 studies · 0 participants | Very low |
Any systemic treatment vs placebo Acitretin · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.53 [0.19, 12.56] | 0 studies · 0 participants | Very low |
Any systemic treatment vs placebo Secukinumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 1.12 [0.74, 1.7] | 8 studies · 2904 participants | Moderate |
Any systemic treatment vs placebo Bimekizumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 58.64 [3.72, 923.86] | 1 study · 250 participants | Low |
Any systemic treatment vs placebo Guselkumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 25.84 [20.9, 31.95] | 5 studies · 1767 participants | Moderate |
Any systemic treatment vs placebo Secukinumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 23.97 [20.03, 28.7] | 8 studies · 2895 participants | High |
Any systemic treatment vs placebo Brodalumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 21.96 [18.17, 26.53] | 5 studies · 4109 participants | Moderate |
Any systemic treatment vs placebo Adalimumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 17.82 [14.62, 21.72] | 9 studies · 3421 participants | Moderate |
Any systemic treatment vs placebo Ustekinumab · people with chronic plaque psoriasis Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (2020) · Cochrane | RR 17.17 [14.44, 20.42] | 9 studies · 4231 participants | High |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants cleared or almost cleared ‐ · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 1.2 [0.72, 2] | 1 study · 19 participants | Very low |
Topical vitamin D derivative vs placebo Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Topical vitamin D derivative vs placebo Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | RR 0.87 [0.64, 1.19] | 1 study · 188 participants | Moderate |
Topical vitamin D derivative vs placebo Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants cleared or almost cleared at 8 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 2 studies · 22 participants | Very low |
Puvatherapy vs placebo or no treatment Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants achieving a 50% reduction in disease severity at 8 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 1 study · 22 participants | Very low |
Puvatherapy vs placebo or no treatment Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Triamcinolone acetonide 0.1% cream with occlusive dressing vs clobetasol cream 0.05% cream Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · for chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Puvatherapy vs placebo or no treatment Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 2 studies · 22 participants | Very low |
Puvatherapy vs placebo or no treatment Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | NR | No studies |
UVA1 vs narrowband UVB Proportion of participants cleared or almost cleared at 10 weeks · chronic palmoplantar pustulosis Interventions for chronic palmoplantar pustulosis (2020) · Cochrane | no estimate extracted | 1 study · 33 participants | Very low |